BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
Neurogene's (NASDAQ:NGNE) Earnings Might Be Weaker Than You Think
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $65
BMO Capital analyst Keith Tapper CFA maintains $Neurogene(NGNE.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rate of 80.0% and a
Buy Rating for Neurogene: Promising Rett Syndrome Program and Strong Financial Outlook
Buy Rating Affirmed for Neurogene Amid Promising Outlook for Gene Therapy Candidate NGN-401
Neurogene's NGN-401 Wins Key FDA Designation